Esteban-Fernández, Alberto http://orcid.org/0000-0002-3839-7336
Gómez-Otero, Inés
López-Fernández, Silvia
Santamarta, Miguel Rodríguez
Pastor-Pérez, Francisco J.
Fluvià-Brugués, Paula
Pérez-Rivera, José-Ángel
López López, Andrea
García-Pinilla, José Manuel
Palomas, Juan Luis Bonilla
Bonet, Luis Almenar
Cobo-Marcos, Marta
Mateo, Virgilio Martínez
Llergo, Javier Torres
Fernández, Vanesa Alonso
Vives, Cristina Goena
de Juan Bagudá, Javier
Benedicto, Alba Maestro
de Polavieja, José Ignacio Morgado
Solla-Ruiz, Itziar
Solé-González, Eduard
Cardona, Montserrat
Olaetxea, Javier Rekondo
Cortés, Carolina Ortiz
Dosantos, Victor Martínez
López, Antonio Gámez
Amao, Elvis
Sánchez, Borja Casas
Torres, Edgardo Alania
Carrillo, Víctor Gómez
García-Fuertes, Daniel
Ridocci-Soriano, Francisco
,
Arana-Achaga, Xabier
Jiménez, Francisco José Bermúdez
Marcos, Marta Cobo
Álvarez, Concepción Cruzado
Jiménez, Juan F. Delgado
Trenado, Víctor Donoso
Rozas, Inmaculada Fernández
Fort, Aleix
García, Belén
Carmena, María Dolores García-Cosío
Rubio, Clara Jiménez
Martínez, Laura Jordán
Reynolds, Bernardo Lanza
López-Azor, Juan Carlos
Vilella, Raquel López
Bahamonde, Ainara Lozano
Clement, Irene Marco
Sabastia, Elisabet Mena
Villar, María Molina
Villota, Julio Nuñez
Merino, Pedro Agustín Pájaro
Cabeza, Alejandro Pérez
Martínez, Montserrat Puga
Mezcua, Ainhoa Robles
Corral, Ester Sánchez
Muñoz, Enrique Sánchez
Aumente, José María Segura
Torrecilla, Estefanía
Benito, Iñaki Villanueva
Funding for this research was provided by:
Sociedad Española de Cardiología (SECAINC-INV-ICC 21/003)
Novartis
Boehringer Ingelheim
Article History
Received: 13 April 2023
Accepted: 30 May 2023
First Online: 21 June 2023
Declarations
:
: AE-F has received scientific speaking fees from Novartis, Bayer, Vifor, Fresenius, and Boehringer-Ingelheim. IGO has received funding or fees from Pfizer, Novartis, Rovi, Vifor, Orion, and Boheringer-Ingelheim. JJB reports consulting and speaking fees from Almirall, AstraZeneca, ArrhytNeT, Bayer, Boehringer-Ingelheim, Boston Scientific, Daiichi Sankyo, Esteve, Impulse Dynamics, Orion Pharma, Novartis, Rovi, Servier, and Vifor. The other authors declare no conflict of interest with this article.